恒瑞医药(600276.SH)获得瑞维鲁胺片药物临床试验批准通知书

智通财经
Nov 13, 2025

智通财经APP讯,恒瑞医药(600276.SH)发布公告,近日,公司收到国家药品监督管理局核准签发关于瑞维鲁胺片的《药物临床试验批准通知书》,将于近期开展临床试验。

瑞维鲁胺片是第二代AR抑制剂,相较于第一代AR抑制剂,具有更强的AR抑制作用,且无激动作用。公司瑞维鲁胺片已于2022年获批上市,用于治疗高瘤负荷的转移性激素敏感性前列腺癌(mHSPC)患者。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10